Pfizer Inc. (NYSE:PFE) Stock Holdings Boosted by Capital Investment Advisors LLC

Capital Investment Advisors LLC boosted its position in Pfizer Inc. (NYSE:PFEFree Report) by 0.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 678,325 shares of the biopharmaceutical company’s stock after purchasing an additional 5,984 shares during the quarter. Capital Investment Advisors LLC’s holdings in Pfizer were worth $24,881,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. 25 LLC acquired a new position in shares of Pfizer during the first quarter worth approximately $25,000. Worth Asset Management LLC bought a new stake in Pfizer during the 1st quarter valued at $29,000. Freedom Wealth Alliance LLC acquired a new position in Pfizer during the 4th quarter worth $35,000. Macroview Investment Management LLC grew its stake in shares of Pfizer by 70.0% in the first quarter. Macroview Investment Management LLC now owns 962 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 396 shares in the last quarter. Finally, GeoWealth Management LLC acquired a new position in shares of Pfizer during the first quarter valued at $49,000. 68.05% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 1.3 %

Shares of NYSE:PFE opened at $33.64 on Tuesday. The firm has a 50 day simple moving average of $35.80 and a 200 day simple moving average of $37.96. Pfizer Inc. has a 52 week low of $33.44 and a 52 week high of $54.93. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.82 and a current ratio of 2.12. The company has a market cap of $189.93 billion, a PE ratio of 8.95, a price-to-earnings-growth ratio of 1.14 and a beta of 0.59.

Pfizer (NYSE:PFEGet Free Report) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.10. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $13.36 billion. During the same quarter in the prior year, the company earned $2.04 earnings per share. The company’s revenue for the quarter was down 54.1% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 3.33 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th were paid a dividend of $0.41 per share. The ex-dividend date was Thursday, July 27th. This represents a $1.64 annualized dividend and a yield of 4.88%. Pfizer’s dividend payout ratio (DPR) is presently 43.62%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Credit Suisse Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $47.00 to $40.00 in a research report on Thursday, June 29th. JPMorgan Chase & Co. decreased their price objective on shares of Pfizer from $45.00 to $41.00 and set a “neutral” rating for the company in a report on Monday, July 17th. StockNews.com initiated coverage on Pfizer in a report on Thursday, August 17th. They set a “hold” rating on the stock. Morgan Stanley decreased their price target on Pfizer from $42.00 to $40.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 2nd. Finally, Barclays cut their price objective on Pfizer from $40.00 to $38.00 in a report on Tuesday, July 11th. Twelve investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $46.35.

View Our Latest Stock Analysis on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.